Safety of oral ciprofloxacin. An update based on clinical trial results.

摘要: The safety of ciprofloxacin was established on a data base (compiled through the end 1988) 9,473 well-documented treatment courses world-wide. daily dosages ranged between 200 and 2,000 mg orally. Thirty-eight percent patients received doses 1 10 mg/kg body weight, 46 11 20 mg/kg, remaining 16 more than weight daily. Ciprofloxacin administered to 4,214 women (45 percent) 5,252 men (55 percent). duration from less two days 90 days. A 600-mg dose used mostly in Japan (2,341 patients). 1,000 chiefly United States Europe (2,288 age one year 99 years (mean, 50.6 years). More 38 were older 60 years. According COSTART terminology, following drug-related side effects observed different organ systems: digestive, 4.9 percent; metabolic-nutritional, 4.4 central nervous system, 1.5 percent, skin, 1.1 hemic lymphatic, 0.9 urogenital, 0.8 as whole, 0.5 cardiovascular, 0.2 special senses, musculoskeletal, 0.1 respiratory, percent. Several had reaction. total incidence for treated 9.3 vast majority adverse reactions mild or moderate (94 Serious reported 55 (6 Based courses, severe 0.6 discontinued due 146 (1.5 percent), gastrointestinal (80 worldwide clinical trials with oral clearly demonstrate that drug is relatively safe, are usually intensity reversible.